Novartis

Hitica Tab 90mg 10s

Name: Hitica Tab 90mg 10s
Brand: Novartis
SKU: HP-09984
Price: 700.00 PKR
Availability: InStock
Rating: 4.5 (33 reviews)

4.5 (33)SKU HP-09984

A tablet containing Ticagrelor, indicated for Blood Clot.

Rs. 700

1 Pack

In StockSet your city for an exact delivery date

In stock at selected branches

Quantity

100% authentic
Free over Rs. 1,500
Pharmacist verified
7-day returns

Total for 1 pack: Rs. 700

What it is used for: Blood Clot.

Indications as listed by the manufacturer: Ticagrelor is indicated to reduce the rate of: • Cardiovascular death • Myocardial infarction • Stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI) • Also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS

How it works: Ticagrelor reversibly interacts with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent.

Active ingredient: Ticagrelor.

Reported side effects: Neoplasms benign, malignant and unspecified (including cysts and polyps): Uncommon: Tumour bleedings, Blood and lymphatic system disorders: Very common: Blood disorder bleedings, Immune system disorders: Uncommon: Hypersensitivity including angioedemac, Metabolism and nutrition disorders: Very common: Hyperuricaemiad ; Common: Gout/Gouty Arthritis, Psychiatric disorders : Uncommon: ConfusionNervous system disorders : Common: Dizziness, Syncope, Headache ; Uncommon: Intracranial haemorrhage, Eye disorders : Uncommon: Eye haemorrhagee, Ear and labyrinth disorders : Common: Vertigo; Uncommon: Ear haemorrhageVascular disorders : Common: HypotensionRespiratory, thoracic and mediastinal disorders : Very common: Dyspnoea ; Common: Respiratory system bleedings.

Known drug interactions: Strong CYP3A Inhibitors : Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk ofdyspnea, bleeding, and other adverse events. Avoid use of strong inhibitors of CYP3A (e.g.,ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin).Strong CYP3A Inducers : Strong CYP3A inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor. Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital).Aspirin : Use of Ticagrelor with aspirin maintenance doses above 100 mg reduced the effectiveness of ticagrelor. Simvastatin, Lovastatin : Ticagrelor increases serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg. Digoxin : Ticagrelor inhibits the P-glycoprotein transporter; monitor digoxin levels with initiation of or change in Ticagrelor therapy.

History of Intracranial Hemorrhage : Ticagrelor is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population. Active Bleeding : Ticagrelor is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. Hypersensitivity : Ticagrelor is contraindicated in patients with hypersensitivity (e.g., angioedema) to ticagrelor or : any component of the product. Severe Hepatic Impairment : Ticagrelor is contraindicated in patients with severe hepatic patients because of probable increase in exposure. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins.
Patients treated with Ticagrelor may develop dyspnea. Dyspnea is usually mild to moderate in intensity and often resolves during continued treatment, but lead to drug discontinuation . If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to Ticagrelor, no specific treatment is required; continue Ticagrelor without interruption if possible. In the case of intolerable dyspnea requiring discontinuation of Ticagrelor, consider prescribing another antiplatelet agent.
Discontinuation of Ticagrelor will increase the risk of myocardial infarction, stroke, and death. If Ticagrelor must be temporarily discontinued (e.g., to treat bleeding or for significant surgery), restart it as soon as possible. When possible, interrupt therapy with Ticagrelor for five days prior to surgery that has a major risk of bleeding. Resume Ticagrelor as soon as hemostasis is achieved.
Only limited information is available for use in patients with moderate hepatic impairment. Dose adjustments are not recommended but ticagrelor should be used with caution.
Drugs that inhibit platelet function including Ticagrelor increase the risk of bleeding. If possible, manage bleeding without discontinuing Ticagrelor. Stopping Ticagrelor increases the risk of subsequent cardiovascular events.

What it is used for: Blood Clot.

Active ingredient: Ticagrelor.

History of Intracranial Hemorrhage : Ticagrelor is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population. Active Bleeding : Ticagrelor is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. Hypersensitivity : Ticagrelor is contraindicated in patients with hypersensitivity (e.g., angioedema) to ticagrelor or : any component of the product. Severe Hepatic Impairment : Ticagrelor is contraindicated in patients with severe hepatic patients because of probable increase in exposure. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins.
Patients treated with Ticagrelor may develop dyspnea. Dyspnea is usually mild to moderate in intensity and often resolves during continued treatment, but lead to drug discontinuation . If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to Ticagrelor, no specific treatment is required; continue Ticagrelor without interruption if possible. In the case of intolerable dyspnea requiring discontinuation of Ticagrelor, consider prescribing another antiplatelet agent.
Discontinuation of Ticagrelor will increase the risk of myocardial infarction, stroke, and death. If Ticagrelor must be temporarily discontinued (e.g., to treat bleeding or for significant surgery), restart it as soon as possible. When possible, interrupt therapy with Ticagrelor for five days prior to surgery that has a major risk of bleeding. Resume Ticagrelor as soon as hemostasis is achieved.
Only limited information is available for use in patients with moderate hepatic impairment. Dose adjustments are not recommended but ticagrelor should be used with caution.
Drugs that inhibit platelet function including Ticagrelor increase the risk of bleeding. If possible, manage bleeding without discontinuing Ticagrelor. Stopping Ticagrelor increases the risk of subsequent cardiovascular events.